Traws Pharma

A clinical stage company aiming to address unmet medical needs in respiratory viral diseases and cancer.

[Traws Pharma @trawspharma]

We're excited to announce positive topline data from the ferret model testing, demonstrating tivoxavir marboxil's potential to inhibit disease after H5N1 bird flu infection. #BirdFlu

Learn more at https://t.co/N91YRr8FqE

[Traws Pharma @trawspharma]

Happy to announce that we have regained compliance with the minimum stockholders’ equity requirements of Nasdaq Listing Rule 5550(b)(1), and Traws common stock will continue to be traded on The NASDAQ Capital Market under the symbol “TRAW”.

Learn more at https://t.co/Mr3OcdAGh5

[Traws Pharma @trawspharma]

We are excited to announce the completion of Phase I clinical studies of our investigational one-dose influenza (flu) therapy, tivoxavir marboxil (tivoxavir), for the treatment or prevention of H5N1 bird flu.

Learn more at https://t.co/fuF2ehoAFD

[Traws Pharma @trawspharma]

We are excited to announce that we've entered into definitive agreements to raise up to $72.6 million from leading healthcare institutional investors to advance Tivoxavir Marboxil development for H5N1 Bird Flu to approval.

Learn more at https://t.co/DBadIcATWG

[Traws Pharma @trawspharma]

We're excited to share progress in the development of our one-dose influenza (flu) investigational therapy, tivoxavir marboxil for treatment of H5N1 bird flu.
https://t.co/lyWBY7BMSl

[Traws Pharma @trawspharma]

Our recent business updates and reported unaudited financial results for the third quarter are out - we're pleased with the progress of our clinical pipeline, particularly the streamlined development of the antiviral programs for COVID and influenza.
https://t.co/WVCC3j6TVd

[Traws Pharma @trawspharma]

We are excited to announce positive topline Phase 1 results for our flu candidate, tivoxavir marboxil, a potential best-in-class inhibitor of the highly-conserved influenza protein, CAP-dependent endonuclease (CEN).
https://t.co/4e3nKbMVva

[Traws Pharma @trawspharma]

We are excited to announce positive topline Phase 1 results for our COVID candidate, Ratutrelvir, an oral inhibitor of the Main protease (Mpro).
https://t.co/BvIIqmJZ91

[Traws Pharma @trawspharma]

Traws Pharma, Inc. (“Traws” or “Traws Pharma”) announced presentation of a poster at the annual International Conference on Antiviral Research (ICAR2024) which is being held from May 20th to May 24th in Gold Coast, Australia.
https://t.co/75zRHUseyr

[Traws Pharma @trawspharma]

We've completed dosing in the first cohort of the first-in-human Phase 1 study to evaluate travatrelvir (TRX01), an orally-available protease inhibitor, in development for treatment of COVID19. There have been no safety observations reported.
https://t.co/llrpOS45HO

[Traws Pharma @trawspharma]

Traws Pharma, Inc. (Nasdaq: TRAW, “Traws”, the “Company”) today announced it has granted equity awards to new employees who joined Traws in connection with the recent acquisition of Trawsfynydd Therapeutics, Inc. by Onconova Therapeutics, Inc.
https://t.co/PVZLMEcDZ0

[Traws Pharma @trawspharma]

Onconova Therapeutics, Inc. And Trawsfynydd Therapeutics, Inc. Announce Business Combination To Form Traws Pharma, Inc, A Best-In-Class Virology And Oncology Company.

Learn more at https://t.co/mduLzoVJmv